Short answer
Vera Therapeutics, Inc. (VERA) filed its fiscal 2025 10-K annual report with the SEC on Feb 26, 2026.
- Top risk flagged: Cybersecurity risk exposure from IT systems or third-party partners, potential regulatory investigations, litigation, fines, business disruption, reputational harm
FY2025 key financial metrics · XBRL
- Net income
- −$300M
- −96.9% YoY
- EPS (diluted)
- −$4.66
- −69.5% YoY
- ROE
- -49.6%
- −23.2 pp YoY
- Operating cash flow
- −$241M
- −79.0% YoY
Source: XBRL data from the Vera Therapeutics, Inc. (VERA) FY2025 10-K on SEC EDGAR. USD.
Vera Therapeutics, Inc. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Risk Factors
- Cybersecurity risk exposure from IT systems or third-party partners, potential regulatory investigations, litigation, fines, business disruption, reputational harm
- Oversight by audit committee and Cybersecurity Risk Management Committee using manual/automated tools and third-party assessments
- Key operational risk from reliance on specialized cybersecurity personnel with 29 and 28 years’ experience in biotech IT and security
- Incident response plan escalates incidents to management and board audit committee, ensuring rapid mitigation and remediation
- Regular management updates and external briefings to monitor and mitigate evolving cybersecurity threats
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.